MARKET

OXFD

Oxford Immunotec
OXFD
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-436.3095
10.01
2.985
562,456,569.66
News On Oxford Immunotec Global PLC (OXFD) Now Under PKI
News On Oxford Immunotec Global PLC (OXFD) Now Under PKI
Dow Jones · 03/08 22:08
Shares of OXFD Up 62.9% Since Uptrend Call on Shares
Mar 05, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for Oxford Immunotec (NASDAQ:OXFD) on November 5th, 2020 at $13.49. In...
marketwatch.com · 03/05 05:33
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection
Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, announced that today it has released the T-SPOT.COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell)...
PR Newswire · 03/04 20:01
PerkinElmer, Inc. -- Moody's assigns Baa3 rating to PerkinElmer's notes offering
Rating Action: Moody's assigns Baa3 rating to PerkinElmer's notes offeringGlobal Credit Research - 04 Mar 2021New York, March 04, 2021 -- Moody's Investors Service, ("Moody's") assigned a Baa3 rating to the proposed offering of senior unsecured 10- and 30-...
Moody's · 03/04 15:09
Fitch Rates PerkinElmer's Unsecured Notes 'BBB'
reuters.com · 03/04 14:24
8-K: Oxford Immunotec Global PLC
falseX00001586049NASDAQ00015860492021-02-262021-02-26 -------------------------------------------------------------------------------- UNITED STATES...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/27 08:06
Oxford Immunotec Has Returned 62.6% Since SmarTrend Recommendation (OXFD)
Feb 25, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for Oxford Immunotec (NASDAQ:OXFD) on November 5th, 2020 at $13.49. In...
marketwatch.com · 02/25 18:01
Tuberculosis Diagnostics Market Growth Survey 2021 with Top Countries Data Industry Size, Share, Business Growth, Revenue, Trends, Market Demand Penetration and Forecast | With Covid 19 Analysis
The Express Wire · 02/24 02:49
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OXFD. Analyze the recent business situations of Oxford Immunotec through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OXFD stock price target is 22.50 with a high estimate of 25.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 124
Institutional Holdings: 30.68M
% Owned: 119.93%
Shares Outstanding: 25.58M
TypeInstitutionsShares
Increased
21
1.74M
New
14
1.87M
Decreased
28
2.03M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.23%
Healthcare Equipment & Supplies
-0.50%
Key Executives
Chairman/Independent Director
Patrick Balthrop
Chief Executive Officer/Director
Peter Wrighton-Smith
Chief Financial Officer
Matthew McLaughlin
General Counsel/Secretary
Janet Kidd
Independent Director
Ronald Andrews
Independent Director
Mark Klausner
Independent Director
Patricia Randall
Independent Director
Herman Rosenman
Independent Director
Richard Sandberg
Independent Director
James Tobin
Independent Director
Andrew Walton
No Data
  • All
  • Financials
  • Insiders
More

Webull offers kinds of Oxford Immunotec stock information, including NASDAQ:OXFD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OXFD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OXFD stock methods without spending real money on the virtual paper trading platform.